Skip to main content
Premium Trial:

Request an Annual Quote

Biocept, OHSU Reach Deal on Liquid Biopsy

NEW YORK (GenomeWeb) – Biocept today announced a preferred provider collaboration and services agreement with Oregon Health & Sciences University granting the university the rights to offer Biocept's Target Selector liquid biopsy testing services throughout Oregon.

The partners also plan to engage in technology transfer that would allow OHSU to use Target Selector assays in house, and to act as a secondary laboratory for Biocept's research and testing services. Biocept and OHSU also said they plan to codevelop liquid biopsy assay technologies and platform capabilities, including highly sensitive, multiplexed assay panels for molecular biomarker detection and assessment.

The partners also expect to engage in additional R&D commercial pilot projects. Financial and other terms of the agreement were not disclosed. OHSU is acting on behalf of the OHSU Knight Cancer Institute on the deal. 

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.